JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vyas, S. J.
Right arrow Articles by Jackson, E. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vyas, S. J.
Right arrow Articles by Jackson, E. K.

Vol. 285, Issue 2, 828-834, May 1998

Guanine Nucleotide-Binding Inhibitory Protein-Mediated Inhibition of Adenylyl Cyclase Is Enhanced in Spontaneously Hypertensive Rat Preglomerular Arteriolar Smooth Muscle Cells1

Subhash J. Vyas, Rupa Mokkapatti, Raghvendra K. Dubey, Mala R. Chinoy and Edwin K. Jackson

Center for Clinical Pharmacology and Departments of Pharmacology (R.M., E.K.J.) and Medicine (S.J.V., R.K.D.), University of Pittsburgh School of Medicine, Pittsburgh and Section of Pediatric Surgery (M.R.C.), Division of Surgery, The Pennsylvania State University College of Medicine, The Milton S. Hershey Medical Center, Hershey, Pennsylvania

The purpose of our study was to determine whether Gi -mediated control over adenylyl cyclase in preglomerular arteriolar smooth muscle cells (PGASMC) is enhanced in the spontaneously hypertensive rat (SHR). PGASMC were cultured from preglomerular microvessels isolated from adult SHR (14-15 wk of age) and age-matched WKY rats. Confluent monolayers of cells in third passage were used for the experiments. cAMP released into the media (30 min) as well as cellular levels of cAMP were measured in the presence of a phosphodiesterase inhibitor, 1-isobutyl-3-methyl-xanthine (IBMX; 100 µM) and expressed as pmol/mg protein. Total (released + cellular) cAMP was significantly lower in SHR (14.19 ± 2.30 pmol/mg protein) as compared with WKY (28.3 ± 3.04 pmol/mg protein). Correspondingly, the released (4.6 ± 0.4 pmol/mg protein) as well as cellular (9.78 ± 2.18 pmol/mg protein) cAMP levels were also significantly lower in SHR when compared with WKY (8.85 ± 1.26 and 18.86 ± 2.0 pmol/mg protein, respectively). The steady-state levels of none of the Gialpha subunits, namely Gialpha 1, Gialpha 2 and Gialpha 3, were higher in the SHR PGASMC. Pertussis toxin treatment (PTX; 100 ng/ml; 24 hr) caused complete ADP-ribosylation of Gialpha subunits in both WKY and SHR PGASMC. The same treatment of PTX also produced a significant increase in total cAMP in SHR, but not in WKY, such that the total cAMP levels after PTX treatment were not significantly different between the two strains. Interestingly, PTX significantly increased the released (20.26 ± 0.90 pmol/mg protein) but not the cellular (13.63 ± 1.63 pmol/mg protein) cAMP in SHR. Forskolin (1 µM) induced similar increases in total cAMP and isoproterenol (1 µM) caused greater increases in total cAMP in SHR cells compared with WKY cells. These data strongly suggest that in SHR PGASMC total adenylyl cyclase activity is not altered. Furthermore, steady-state expressions of G ialpha -1, G ialpha -2 and G ialpha -3 are not increased whereas Gi -mediated inhibition of adenylyl cyclase is augmented in SHR PGASMC.


0022-3565/98/2852-0828$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
HypertensionHome page
E. K. Jackson, W. A. Herzer, C. K. Kost Jr, and S. J. Vyas
Enhanced Interaction Between Renovascular {alpha}2-Adrenoceptors and Angiotensin II Receptors in Genetic Hypertension
Hypertension, September 1, 2001; 38(3): 353 - 360.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.